Table 3.
Risk factors for mortality in patients with COVID-19 receiving respiratory support
Variable | Univariate | Multivariate analysis | |
P value* | P value* | HR (95% CI) | |
Age, years | <0.001 | <0.001 | 1.054 (1.028 to 1.082) |
Male (yes/no) | 0.014 | ||
Comorbidities (yes/no) | |||
Hypertension | 0.392 | ||
Diabetes | 0.001 | 0.002 | 2.226 (1.357 to 3.652) |
Chronic obstructive pulmonary disease | 0.009 | ||
Chronic kidney disease | 0.841 | ||
Chronic liver disease | 0.226 | ||
ACE inhibitor/ARB use (yes/no) | 0.871 | ||
Lymphocyte count, ×103/uL | <0.001 | 0.005 | 0.999 (0.998 to 1.000) |
Platelet count, ×109/L | 0.087 | 0.069 | 0.997 (0.994 to 1.000) |
C reactive protein, mg/L | 0.584 | ||
Aspartate aminotransferase, U/L | 0.050 | 0.033 | 1.002 (1.000 to 1.003) |
Alanine aminotransferase, U/L | 0.552 | ||
Total bilirubin, mg/dL | 0.831 | ||
Alkaline phosphatase, U/L | 0.725 | ||
Gamma glutamyl transferase, U/L | 0.263 | ||
Serum albumin, g/dL | 0.773 | ||
Prothrombin time, INR | 0.444 | ||
Estimated glomerular filtration rate, mL/min/1.73 m2 | 0.002 | ||
SIRS on admission (yes/no) | <0.001 | 0.074 | 1.968 (1.199 to 3.230) |
*Calculated by Cox proportional hazards regression test.
ARB, angiotensin II receptor blocker; INR, international normalised ratio; SIRS, systemic inflammatory response syndrome.